Sydney Jennings

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.

FDA approved teplizumab to help preserve insulin production in children with recent-onset stage 3 type 1 diabetes.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Takeda reported phase 3 data showing zasocitinib achieved higher week 16 PASI 100 responses than deucravacitinib in plaque psoriasis.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

New FLOW trial data presented at ERA 2026 showed semaglutide improved health-related quality of life in adults with type 2 diabetes and CKD.

Recent FDA updates include new actions in diabetes, hypertension, chronic HDV infection, bipolar depression, and CKD in type 1 diabetes.

A natural experiment found pediatric influenza vaccination reduced influenza diagnoses among children aged 2 to 5 years.

A national survey found US adults recognize STI transmission routes but remain uncertain about HPV and mpox vaccine prevention.

The FDA today issued a Complete Response Letter for Cingulate’s CTx-1301 for ADHD, citing CMC-related requests and no current safety or efficacy concerns.

FDA approved ensitrelvir for COVID-19 postexposure prophylaxis in adults and adolescents aged 12 years and older after exposure.

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Elunetirom received FDA Fast Track designation as an adjunctive therapy for bipolar depression, with phase 2 AMPLIFY-BD data expected in 2026.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

Orforglipron reduced body weight versus placebo in adults aged 65 years or older with obesity or overweight in ATTAIN-1 and ATTAIN-2.

FDA grants priority review to finerenone for adults with type 1 diabetes and chronic kidney disease based on FINE-ONE data.

Retatrutide reduced body weight by up to 28.3% at 80 weeks in adults with obesity or overweight in the phase 3 TRIUMPH-1 trial.

FDA accepted Bayer's asundexian NDA for recurrent stroke prevention after noncardioembolic ischemic stroke or TIA.

A NHANES analysis suggests a ferritin cutoff below 24 μg/L may identify more iron deficiency in children aged 5 to 14 years.

Embedding addiction treatment in a resident primary care clinic increased confidence in SUD diagnosis, medication use, and harm-reduction counseling.

A Massachusetts claims study found rising pediatric primary care visits with mental health diagnoses, led by anxiety-related care.